tony w
Human Reproduction
BMC Medical Education
The Lancet
The Clinical Journal of Pain
Psychiatric Annals
A healthy diet may reduce the risk of ovarian cancer in African-American women, according to data presented at the Eighth American Association for Cancer Research (AACR) Conference on the Science of…
French biopharmaceutical company Genfit said on Monday it is to launch a phase 3 study of its treatment for liver disease NASH by year-end as part of an accelerated approval procedure which could allow it to be brought to market in 2019. Genfit shares rose 5 pct to 42.71 euros on the news. There is currently no cure for Non-alcoholic Steatohepatitis (NASH), a degenerative liver disease caused by an excessively rich diet.
Clinical Journal of Sport Medicine
Headache: The Journal of Head and Face Pain


